blood-biomarkers
(6)
InsideTracker
InsideTracker is a Cambridge, Massachusetts personalized health and wellness company (legally Segterra, Inc.) that turns your blood, DNA, and wearable data into a science-backed action plan. Founded in 2009 by MIT-trained scientist Dr. Gil Blander, the platform analyzes dozens of blood biomarkers, estimates your biological 'InnerAge,' and recommends specific foods, supplements, and lifestyle changes to optimize performance, healthspan, and longevity. It has become a favorite of athletes and quantified-self enthusiasts and integrates directly with Garmin, Fitbit, Oura, and Apple devices.
NeuroAge Therapeutics
NeuroAge Therapeutics is a San Francisco tech-bio company that measures how old your brain actually is - and tries to make it younger. Founded in 2022 by physician-scientist Dr. Christin Glorioso, the company's flagship NeuroAge Test blends brain MRI, cognitive games, proprietary RNA blood biomarkers, and genetic screening into a single 'brain age' score that aims to flag dementia risk up to 30 years before symptoms appear. The longer-term goal is bolder: small-molecule drugs that reprogram aging neurons back toward a younger state.
Christin Glorioso
Christin Glorioso, MD, PhD, is a physician-scientist and serial entrepreneur who is CEO and co-founder of NeuroAge Therapeutics, a San Francisco brain-health company building AI-powered 'aging clocks' for the human brain. Trained at MIT and the Carnegie Mellon/University of Pittsburgh Medical Scientist Training Program, she spent two decades studying how brains age before leaving academia to turn that research into a diagnostic and drug-development engine. NeuroAge combines MRI brain-volume data, cognitive testing and proprietary RNA blood biomarkers - validated on data from more than 500,000 people - to estimate brain age and dementia risk decades before symptoms. She also founded the nonprofit Longevity Global and led the world's top-ranked US COVID-19 forecasting model in the XPRIZE Pandemic Response Challenge.
AltPep
AltPep is a Seattle biotech company spun out of the University of Washington that is building both diagnostic tests and disease-modifying drugs for amyloid diseases such as Alzheimer's and Parkinson's. Its work is anchored on the alpha-sheet, a non-standard protein structure discovered by founder and CEO Valerie Daggett, which forms in the toxic soluble oligomers that appear at the earliest, pre-symptomatic stages of disease. AltPep's SOBA blood test aims to flag those toxic oligomers years before symptoms, while its SOBIN peptide therapeutics are designed to neutralize them.
Progentec Diagnostics, Inc.
Progentec Diagnostics is an Oklahoma City company building blood-based biomarker tests and digital health tools for autoimmune diseases, starting with lupus. Its lead product, the aiSLE DX Flare Risk Index, uses an 11-biomarker algorithm to predict a lupus flare up to 12 weeks before it happens, giving rheumatologists a chance to intervene early. Spun out of research tied to the Oklahoma Medical Research Foundation, the company pairs lab science with patient-facing tools like the LupusCorner community to move autoimmune care from reactive to proactive.
Paul Sargeant
Paul Sargeant is the President and CEO of Circular Genomics, a San Diego biotech building blood tests around circular RNA - the loop-shaped, unusually stable molecules most of the field once ignored. A Cambridge-trained physiologist with 25 years across Fortune 100 firms and venture-backed startups in the US, Europe and Asia, he took the helm in 2023, shepherded the launch of the MindLight test predicting which depression patients will respond to SSRIs, moved headquarters into Lilly Gateway Labs, and closed a $15M Series A in December 2025 to push the same platform toward early Alzheimer's detection.